Despite most studies did not specifically evaluate NPM1-mutated AML, they showed that patients who might benefit more from these drug combinations are those who are naïve for hypomethylating agents or have <20% blasts and a higher pre-therapy infiltration of bone marrow by CD3+, CD4+ Teff, and CD8+ T cells [132]. The gene discussed is CD4; the disease is acute myeloid leukemia.